精神分裂症中的NMDA受体“甘氨酸调节位点”：D-丝氨酸、甘氨酸及其他。
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.
作者信息
Balu Darrick T, Coyle Joseph T
机构信息
Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA; Laboratory for Psychiatric and Molecular Neuroscience, McLean Hospital, Belmont, MA 02478, USA.
Department of Psychiatry, Harvard Medical School, Boston, MA 02115, USA; Laboratory for Psychiatric and Molecular Neuroscience, McLean Hospital, Belmont, MA 02478, USA.
出版信息
Curr Opin Pharmacol. 2015 Feb;20:109-15. doi: 10.1016/j.coph.2014.12.004. Epub 2014 Dec 23.
Abstract
Schizophrenia is a severe psychiatric illness that is characterized by reduced cortical connectivity, for which the underlying biological and genetic causes are not well understood. Although the currently approved antipsychotic drug treatments, which primarily modulate dopaminergic function, are effective at reducing positive symptoms (i.e. delusions and hallucinations), they do little to improve the disabling cognitive and negative (i.e. anhedonia) symptoms of patients with schizophrenia. This review details the recent genetic and neurobiological findings that link N-methyl-D-aspartate receptor (NMDAR) hypofunction to the etiology of schizophrenia. It also highlights potential treatment strategies that augment NMDA receptor function to treat the synaptic deficits and cognitive impairments.
摘要
精神分裂症是一种严重的精神疾病，其特征是皮质连接性降低，目前对其潜在的生物学和遗传原因尚不清楚。尽管目前批准的主要调节多巴胺能功能的抗精神病药物治疗在减轻阳性症状（即妄想和幻觉）方面有效，但对改善精神分裂症患者致残的认知和阴性（即快感缺乏）症状作用甚微。本综述详细介绍了最近将N-甲基-D-天冬氨酸受体（NMDAR）功能低下与精神分裂症病因联系起来的遗传学和神经生物学研究结果。它还强调了增强NMDA受体功能以治疗突触缺陷和认知障碍的潜在治疗策略。
相似文献
1
The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.精神分裂症中的NMDA受体“甘氨酸调节位点”：D-丝氨酸、甘氨酸及其他。
Curr Opin Pharmacol. 2015 Feb;20:109-15. doi: 10.1016/j.coph.2014.12.004. Epub 2014 Dec 23.
2
Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.甘氨酸转运体-1抑制剂和D-丝氨酸对大鼠强迫游泳试验中MK-801诱导的不动行为的影响。
Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.
3
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.谷氨酸与精神分裂症：苯环己哌啶、N-甲基-D-天冬氨酸受体及多巴胺-谷氨酸相互作用
Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5.
4
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.天使指明了道路吗？精神分裂症 PCP/NMDA 模型的病因和治疗意义。
Schizophr Bull. 2012 Sep;38(5):958-66. doi: 10.1093/schbul/sbs069.
5
Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia.精神分裂症患者前额叶皮质和小脑中D-丝氨酸与甘氨酸转运体的表达
Schizophr Res. 2008 Jul;102(1-3):283-94. doi: 10.1016/j.schres.2008.02.009. Epub 2008 Apr 8.
6
Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.甘氨酸转运体1抑制剂TASP0315003在精神分裂症认知功能障碍和阴性症状动物模型中的疗效。
Psychopharmacology (Berl). 2015 Aug;232(15):2849-61. doi: 10.1007/s00213-015-3920-3. Epub 2015 Apr 15.
7
The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.N-甲基-D-天冬氨酸受体与精神分裂症：从病理生理学到治疗
Adv Pharmacol. 2016;76:351-82. doi: 10.1016/bs.apha.2016.01.006. Epub 2016 Mar 4.
8
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.N-甲基-D-天冬氨酸受体 D-丝氨酸/甘氨酸位点在精神分裂症病理生理学和治疗中的作用。
Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18.
9
D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.D-丝氨酸和一种甘氨酸转运体抑制剂可改善MK-801诱导的大鼠新物体识别试验中的认知缺陷。
Behav Brain Res. 2008 Jan 10;186(1):78-83. doi: 10.1016/j.bbr.2007.07.033. Epub 2007 Aug 2.
10
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients.甘氨酸位点是半饱和还是半不饱和？谷氨酸能药物对精神分裂症患者的影响。
Curr Opin Psychiatry. 2006 Mar;19(2):151-7. doi: 10.1097/01.yco.0000214340.14131.bd.
引用本文的文献
1
Central Neurophysiological Alterations in Dystrophic mdx Mice Correlate With Reduced Hippocampal Levels of the Endogenous NMDA Receptor Ligand D-Aspartate.营养不良性mdx小鼠的中枢神经生理改变与海马中内源性NMDA受体配体D-天冬氨酸水平降低相关。
J Neurochem. 2025 Sep;169(9):e70223. doi: 10.1111/jnc.70223.
2
Evaluation of the Drug-Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach.甘氨酸转运体1（GlyT1）抑制剂依克哌汀（BI 425809）的药物相互作用潜力评估：基于生理的药代动力学（PBPK）建模方法
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1391-1402. doi: 10.1002/psp4.70060. Epub 2025 Jun 25.
3
Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y).长效注射用帕利哌酮棕榈酸酯每半年一次给药方案在欧洲精神分裂症患者中的长期疗效、依从性及安全性：来自帕利哌酮每年两次研究（P2Y）的2年镜像数据
Front Psychiatry. 2025 Mar 4;16:1540213. doi: 10.3389/fpsyt.2025.1540213. eCollection 2025.
4
Modulation of the human GlyT1 by clinical drugs and cholesterol.临床药物和胆固醇对人甘氨酸转运体1（GlyT1）的调节作用
Nat Commun. 2025 Mar 11;16(1):2412. doi: 10.1038/s41467-025-57613-z.
5
Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.精神分裂症认知障碍治疗的进展：靶向 NMDA 受体通路。
Int J Mol Sci. 2024 Oct 3;25(19):10668. doi: 10.3390/ijms251910668.
6
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.找到合适剂量：用于治疗精神分裂症认知和可塑性缺陷的NMDA受体调节疗法及药效学靶点参与的作用
Biol Psychiatry. 2025 Jan 15;97(2):128-138. doi: 10.1016/j.biopsych.2024.08.019. Epub 2024 Aug 30.
7
Effect of transcranial direct current stimulation with concurrent cognitive performance targeting posterior parietal cortex vs prefrontal cortex on working memory in schizophrenia: a randomized clinical trial.经颅直流电刺激联合靶向顶叶后皮质和前额皮质的认知表现对精神分裂症工作记忆的影响：一项随机临床试验。
Transl Psychiatry. 2024 Jul 8;14(1):279. doi: 10.1038/s41398-024-02994-w.
8
Impact of Serine Racemase Deletion on Nicotine Discrimination.丝氨酸消旋酶缺失对尼古丁辨别力的影响。
Nicotine Tob Res. 2024 Nov 22;26(12):1744-1748. doi: 10.1093/ntr/ntae156.
9
D-serine reconstitutes synaptic and intrinsic inhibitory control of pyramidal neurons in a neurodevelopmental mouse model for schizophrenia.D-丝氨酸重建精神分裂症神经发育模型中小鼠锥体神经元的突触和内在抑制控制。
Nat Commun. 2023 Dec 12;14(1):8255. doi: 10.1038/s41467-023-43930-8.
10
Morphological and transcriptomic analyses of stem cell-derived cortical neurons reveal mechanisms underlying synaptic dysfunction in schizophrenia.基于干细胞的皮质神经元的形态学和转录组学分析揭示了精神分裂症中突触功能障碍的潜在机制。
Genome Med. 2023 Jul 28;15(1):58. doi: 10.1186/s13073-023-01203-5.
本文引用的文献
1
Reduction of brain kynurenic acid improves cognitive function.降低脑内犬尿氨酸可改善认知功能。
J Neurosci. 2014 Aug 6;34(32):10592-602. doi: 10.1523/JNEUROSCI.1107-14.2014.
2
Biological insights from 108 schizophrenia-associated genetic loci.108 个精神分裂症相关遗传位点的生物学见解。
Nature. 2014 Jul 24;511(7510):421-7. doi: 10.1038/nature13595. Epub 2014 Jul 22.
3
Involvement of ClC-3 chloride/proton exchangers in controlling glutamatergic synaptic strength in cultured hippocampal neurons.ClC-3 氯离子/质子交换体在培养的海马神经元中控制谷氨酸能突触强度中的作用。
Front Cell Neurosci. 2014 May 23;8:143. doi: 10.3389/fncel.2014.00143. eCollection 2014.
4
A polygenic burden of rare disruptive mutations in schizophrenia.精神分裂症中罕见的破坏性突变的多基因负担。
Nature. 2014 Feb 13;506(7487):185-90. doi: 10.1038/nature12975. Epub 2014 Jan 22.
5
De novo mutations in schizophrenia implicate synaptic networks.精神分裂症中的新突变涉及突触网络。
Nature. 2014 Feb 13;506(7487):179-84. doi: 10.1038/nature12929. Epub 2014 Jan 22.
6
D-serine and serine racemase are localized to neurons in the adult mouse and human forebrain.D-丝氨酸和丝氨酸消旋酶定位于成年小鼠和人类前脑的神经元中。
Cell Mol Neurobiol. 2014 Apr;34(3):419-35. doi: 10.1007/s10571-014-0027-z. Epub 2014 Jan 17.
7
The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.主要脑胆固醇代谢产物 24(S)-羟基胆固醇是 N-甲基-D-天冬氨酸受体的有效别构调节剂。
J Neurosci. 2013 Oct 30;33(44):17290-300. doi: 10.1523/JNEUROSCI.2619-13.2013.
8
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.苯甲酸盐辅助治疗精神分裂症：D-氨基酸氧化酶抑制剂的随机、双盲、安慰剂对照试验。
JAMA Psychiatry. 2013 Dec;70(12):1267-75. doi: 10.1001/jamapsychiatry.2013.2159.
9
D-serine in glia and neurons derives from 3-phosphoglycerate dehydrogenase.胶质细胞和神经元中的 D-丝氨酸来源于 3-磷酸甘油酸脱氢酶。
J Neurosci. 2013 Jul 24;33(30):12464-9. doi: 10.1523/JNEUROSCI.4914-12.2013.
10
CASK regulates SAP97 conformation and its interactions with AMPA and NMDA receptors.CASK 调节 SAP97 的构象及其与 AMPA 和 NMDA 受体的相互作用。
J Neurosci. 2013 Jul 17;33(29):12067-76. doi: 10.1523/JNEUROSCI.0816-13.2013.
Zotero 插件